Changes in mental health symptoms from ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Changes in mental health symptoms from pre-covid-19 to covid-19 among participants with systemic sclerosis from four countries: a scleroderma patient-centered intervention network (spin) cohort study
Author(s) :
Thombs, Brett D. [Auteur]
Kwakkenbos, Linda [Auteur]
Henry, Richard S. [Auteur]
Carrier, Marie-Eve [Auteur]
Patten, Scott [Auteur]
Harb, Sami [Auteur]
Bourgeault, Angelica [Auteur]
Tao, Lydia [Auteur]
Bartlett, Susan J. [Auteur]
Mouthon, Luc [Auteur]
Varga, John [Auteur]
Benedetti, Andrea [Auteur]
Kwakkenbos, Linda [Auteur]
Henry, Richard S. [Auteur]
Carrier, Marie-Eve [Auteur]
Patten, Scott [Auteur]
Harb, Sami [Auteur]
Bourgeault, Angelica [Auteur]
Tao, Lydia [Auteur]
Bartlett, Susan J. [Auteur]
Mouthon, Luc [Auteur]
Varga, John [Auteur]
Benedetti, Andrea [Auteur]
Journal title :
Journal of Psychosomatic Research
Abbreviated title :
J Psychosom Res
Volume number :
139
Pages :
110262
Publication date :
2020-10-03
ISSN :
1879-1360
Keyword(s) :
Pandemic
Epidemiology
Depressive symptoms
Scleroderma
Systemic sclerosis
Adult
Anxiety
Clinical epidemiology
COVID-19
Depressed mood
Epidemiology
Depressive symptoms
Scleroderma
Systemic sclerosis
Adult
Anxiety
Clinical epidemiology
COVID-19
Depressed mood
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations.
To compare anxiety and depression symptoms among people with a pre-existing medical condition and ...
Show more >No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and ≥ 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of ≥1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a ≥ 1 MCID increase. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.Show less >
Show more >No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and ≥ 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of ≥1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a ≥ 1 MCID increase. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:48:43Z